社会参与孤儿药物开发:系统审查
Sanae Akodad1, Delphine De Smedt2, Hilde Stevens1
1Institute for Interdisciplinary Innovation in Healthcare (I3h), Faculté de Médecine, Solvay Brussels School of Economics and Management, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Frontiers in medicine
|September 26, 2025
概括
社会参与孤儿药物 (OD) 开发,特别是罕见疾病,加快时间表,提高相关性. 然而,像代表性差距和治理问题这样的挑战需要持久,透明的模式来有效参与.
科学领域:
- 罕见疾病药物开发 罕见疾病药物开发
- 社会参与研究的社会参与.
- 卫生政策和监管卫生政策和监管
背景情况:
- 孤儿药物 (OD) 开发面临知识和资金有限等障碍.
- 非商业社会参与者 (患者,倡导团体) 越来越多地参与罕见病治疗的开发.
- 本综述侧重于社会参与神经肌肉和神经退行性疾病的OD开发.
研究的目的:
- 系统地审查和综合关于社会参与孤儿药物开发的经验证据.
- 确定社会参与者在孤儿药物生命周期中的角色和贡献.
- 分析与社会参与罕见病治疗开发相关的好处和挑战.
主要方法:
- 对21项同行评审的研究进行了系统审查.
- 包括多样化的研究设计,从案例报告到利益相关者调查.
- 社会角色的功能类型的发展 (发起者,加速者,翻译者,监视者).
主要成果:
- 社会参与者为资金,试验设计,监管参与和传播做出贡献.
- 参与与更快的发展,更好的试验招聘和更相关的终点有关.
- 确定的挑战包括代表性差距,代币主义,治理问题以及缺乏评估框架.
结论:
- 社会参与是孤儿药物开发,监管合法性和治疗相关性的组成部分.
- 目前的参与模式需要改进,以实现持久,透明和可评估的参与方法.
- 解决代表性差距和治理对于最大限度地发挥社会参与的潜力至关重要.
相关概念视频
Prescription, Nonprescription and Orphan Drugs
1.2K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.2K
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Preclinical Development: Overview
5.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.8K
Pharmacokinetics in Pediatric Patients: Drug Metabolism
193
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
193
Drug Discovery: Overview
11.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.0K


